PVLA MEXC RealStocks
Own real PVLA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 16:10:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Palvella Therapeutics, Inc. (PVLA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $150.91, with a market capitalization of $2.24B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $72.23 to $179.95. This page covers its latest market performance, valuation, price trends and company information.
$2.24B | |
$153.00 | |
$155.51 | |
$150.15 | |
$153.18 | |
44.69K | |
237.12K | |
-- | |
$179.95 | |
$72.22 | |
-- | |
-- |
Palvella Therapeutics, Inc. (PVLA) is currently trading at $150.91 as of 2026-11-13 16:09:00, down 0.83% ($1.27) from the previous close of $153.18
During today's regular trading session, PVLA has traded between $150.15 and $155.51, with a trading volume of 44.69K shares. The current price is near the lower end of today's range.
Over the past seven days, Palvella Therapeutics, Inc. (PVLA) moved from $156.85 to $150.91, representing a decline of 3.79% ($5.94).
The stock traded between $150.15 and $179.95 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 290.54 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 73.0%
PVLA is currently trading at $150.91, placing it 73.0% of the way from its 52-week low of $72.23 to its 52-week high of $179.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Palvella Therapeutics, Inc. (PVLA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PVLA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PVLA shares and USD.
PVLA Shares to USD
1.00 PVLA shares = 150.911 USD
Calculations are estimates based on the latest available price and are for reference only.